The massive pharmacy benefit manager plans to stop requiring coverage authorizations for roughly 80 drugs used to treat ...
The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...
Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback